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Betydning av mengde og type fett i kosten ved type 2 diabetes, 
med fokus på marine n-3 fettsyrer 
Doktoravhandlingen bygger på tre kliniske studier av personer med type 2 diabetes. 
Artikkel 1. Hensikten var å undersøke effekter av en 3-dagers intervensjon med 
fettfattig kost. Blodsukker, insulinfølsomhet, fettstoffer og fettvevshormoner ble målt. 
Nitten personer (10 menn og 9 kvinner, 40-75 år) uten insulinbehandling deltok, og 
alle hadde forhøyede nivå av triglyserider (et fettstoff) i blodet. Den fettfattige kosten 
hadde vesentlig mindre fett enn forsøkspersonenes vanlige kost. Til gjengjeld var 
innholdet av kornprodukter, frukt, grønnsaker, magre kjøtt- og meieriprodukter og 
fisk (både fet og mager), økt. Selv om denne kosten bare ble spist i 3 dager, var det 
signifikante forskjeller i blodprøvene tatt etterpå, sammenlignet med tilsvarende 
blodprøver etter vanlig kost. Følgelig ble fastende blodsukker, total kolesterol, HDL-
kolesterol og hormonet leptin redusert. Nivået av hormonet adiponektin økte. 
Gjennomsnittlig blodsukker målt hver dag i kostperioden ble ikke endret, heller ikke 
insulinfølsomheten eller triglyseridnivået. Forsøkspersonene var sine egne kontroller. 
Artikkel 2. Hensikten var å sammenligne insulinfølsomhet, insulinfrigjøring, 
blodsukker og energiomsetning etter 9 uker med enten fiskeolje (12 personer) eller 
maisolje (14 personer) som daglig tilskudd (20 ml). Fiskeoljens innhold av marine n-3 
fettsyrer (omega-3 fettsyrer) var på 6 g/dag. Kosten ellers, samt vekta, var uforandret i 
forsøksperioden. Forsøket var dobbelt blindt. Ingen av forsøkspersonene (13 menn og 
13 kvinner, 39-73 år) var behandlet med insulin, og alle hadde normale nivå av 
triglyserider. Gruppa som fikk fiskeolje kom ut med signifikant høyere blodsukker og 
dårligere insulinfølsomhet, samt tendens til større insulinfrigjøring, sammenlignet 
med gruppa som fikk maisolje. Energiomsetningen var uendret, men 
fettforbrenningen (målt i faste) økte signifikant i gruppa som fikk fiskeolje.  
Artikkel 3. Hensikten var å sammenligne undergrupper av lipoproteiner etter 9 uker 
med enten fiskeolje eller maisolje, i samme forsøk som beskrevet i artikkel 2. 
Lipoproteiner (VLDL, LDL, HDL) er fettforbindelser som frakter kolesterol og 
triglyserider i blodet, og de kan deles inn undergrupper. Med fiskeolje ble partiklene 
av store VLDL mindre og konsentrasjonen av store VLDL og små HDL lavere.  
Artikkel 4. Hensikten var å sammenligne effekter av n-3 fettsyrer (3 g) fra fiskeolje 
med soyaolje, når emulsjoner av disse ble gitt intravenøst i 4 timer. Insulinfølsomhet, 
insulinfrigjøring, energiomsetning og fettvevshormoner ble målt. Elleve 
forsøkspersoner (7 menn, 4 kvinner, 38-73 år, normale triglyseridnivå), utførte begge 
tester med to ukers mellomrom, dobbelt blindt. Rekkefølgen av hvilken olje som ble 
testet først, var tilfeldig. Resultatet var at fettsyrene fra fiskeolje ikke gjorde noen 
forskjell på det som ble målt, med unntak av en tendens til redusert fettforbrenning. 
Tolkning av resultatene. Verken mengde eller type fett i kosten gir entydige resultat 
i sine effekter på blodsukker og fettstoffer i kroppen. Vi får bekreftet at det som er bra 
for å forebygge hjerte- og karsykdom, ikke nødvendigvis er like fra for reguleringen 
av blodsukkeret. At fettredusert kost gir et lavere fastende blodsukker, trenger ikke 
bety noe når dagens gjennomsnittlige blodsukker forblir uendret. Det viktigste funnet 
vårt er at mekanismen bak forhøyet blodsukker av stor dose marine n-3 fettsyrer, 
synes å være redusert insulinfølsomhet. Selv om blodsukkerstigningen var moderat, 
kan vi ikke ut fra våre resultater anbefale store, daglige mengder (6 g) marine n-3 
fettsyrer til personer med type 2 diabetes. Vi har ingen grunn til å fraråde små, daglige 
mengder (1 g), som gis i 1 skje tran eller som 2-3 fiskeoljekapsler. 
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 1. Introduction 
 
1.1 General 
Nutritional aspects in diabetes often alternate focus between hyperglycemia and 
dyslipidemia. In the history of diabetes it may be correct to claim that when diet has 
been used as the only treatment, then the aim to achieve normoglycemia may have 
worsened the dyslipidemia. Turned around, the aim to achieve normolipidemia by diet 
may have worsened the hyperglycemia. A third aim of a recommended diet in 
overweight type 2 diabetes is to achieve weight reduction by energy restriction. Weight 
reduction, however, may mask other effects of dietary modifications. Effects of specific 
dietary changes could thus be secondary to weight reduction. When planning dietary 
studies in subjects with diabetes, it is preferable to avoid secondary effects. Further to 
be aware of the complexity of metabolic responses to dietary factors when interpreting 
the results to. We have tried to keep these considerations in mind. 
 
1.2 Type 2 diabetes  
1.2.1 Clarification and prevalence 
Diabetes is classified into type 1 diabetes (due to islet β-cell destruction), type 2 
diabetes (due to varying degrees of insulin resistance and/or insulin secretion defects), 
and into other specific types of diabetes. Type 2 diabetes accounts for >80% of all cases 
in Caucasian populations, affecting 5-7% of the world’s population [1-3]. In 
Scandinavia the prevalence is reported to be 3-6 % [4,5]. Recent estimates in Norway 
for known (not total) diabetes are 3.4% for subjects aged ≥30 and ~ 8% for subjects 
aged 70-79 years [6]. Among South Asian immigrants in Norway the prevalence of 
known diabetes is assessed to be ~ 28% and 14% in women and men, respectively, 
compared with ~ 3% and 6%, respectively, in Norwegian women and men, aged 30-59 
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years [7]. The number of unknown cases may be nearly equal to the number of known 
cases in the age-groups ≥30 years in Norway [6]. 
Type 2 diabetes is a heterogeneous disease which is due both to environmental and 
genetic factors. Major environmental risk factors are obesity and physical inactivity. 
The genetic predisposition (polygenic, involving both insulin resistance and beta cell 
inadequacy) accounts for 40-80% of susceptibility to type 2 diabetes [8]. Both type 1 
and 2 diabetes increase risk of cardiovascular disease [9,10].  
1.2.2 Insulin resistance 
Insulin resistance is defined as the inability of insulin to produce its usual biological 
actions at circulating concentrations that are effective in normal subjects [11].  
Insulin acts by 
- regulating glucose metabolism by inhibiting glucose production by the liver 
- stimulating glucose uptake, particularly in skeletal muscle 
- stimulating intravascular lipolysis and lipogenesis in adipose tissue  
- inhibiting lipolysis in adipose tissue and  
- Inhibiting very low density lipoprotein (VLDL) production of the liver.  
These actions lower serum glucose, triglyceride and non-esterified fatty acids (NEFA or 
free fatty acids (FFA)), and increase lipoprotein lipase (LPL) activity in adipose tissue.  
A resistance to these actions defines much of the phenotype of type 2 diabetes, i.e.:  
- Hyperglycemia because of impaired suppression of endogenous glucose 
production under basal conditions as well as in the postprandial state  
- Hypertriglyceridemia because the production of very low density lipoprotein 
(VLDL) in the liver is not suppressed, which in turn leads to  lower high density 
lipoprotein (HDL) cholesterol and decreases the size of low density lipoprotein 
(LDL) particles (see below). Small dense LDL particles are highly atherogenic 
and can provide a link between insulin resistance and cardiovascular disease 
- Elevated concentrations of plasma non-esterified fatty acids (NEFA, or FFA), 
because the “brake” on lipolysis is missing in insulin resistance. 
10 
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1.2.3 Insulin secretion 
The maintenance of normal glucose homeostasis depends on a balanced interaction 
between tissue sensitivity to insulin (especially in muscle and liver) and insulin 
secretion [12]. Hyperinsulinemia can be viewed as an attempt to overcome insulin 
resistance; however when type 2 diabetes is diagnosed, this adaptation is clearly not 
sufficient. Thus, insulin secretion is already defective at the time of diagnosis of type 2 
diabetes. For reasons not completely elucidated, secretion is further attenuated with 
increasing duration of diabetes.  
The interplay between insulin secretion and sensitivity makes it necessary in 
intervention studies to obtain measures not only of insulin sensitivity but also on insulin 
secretion. In the present studies we have tried to evaluate intervention effects on both 
parameters.  
1.2.4 Energy metabolism 
Energy requirements are determined by body size and composition, age and physical 
activity. Total energy expenditure consists of resting expenditure plus variable 
components due primarily to physical activity and “thermogenesis”, i.e. heat production 
associated with meal digestion, nutrient absorption, and exposure to cold and stress 
[13]. Resting expenditure accounts for 50-70% of total energy expenditure. Energy 
metabolism is usually measured by indirect calorimetry and is termed energy production 
rate (EPR). Indirect calorimetry also allows calculation of the respiratory quotient (RQ), 
i.e. the ratio between CO2 production and O2 consumption. A high RQ signifies higher 
carbohydrate oxidation and simultaneously low fat oxidation and vice versa. An 
estimate of resting energy expenditure can also be obtained by calculating basal 
metabolic rate (BMR) by equations based on gender, age, weight (and height) [14].  
A gradual increase in fasting RQ (i.e. lower fat oxidation) is reported after weight gain 
in subjects with and without type 2 diabetes [15]. A high RQ is claimed to be a 
predictor of weight gain in subjects with type 2 diabetes who are under treatment  since 
a significant higher postabsorptive RQ is reported among those, compared with non-
treated type 2 diabetes and healthy controls, with no difference between the non-treated 
diabetic  and the healthy subjects [16]. 
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1.2.5 Lipid variables 
A “healthy” lipid profile is characterized by rapid removal of plasma lipids 
(triglycerides and cholesterol) from the circulation. The exogenous lipoprotein pathway 
includes triglycerides (and cholesterol) of dietary origin absorbed from the gut, and then 
repackaged into the large triglyceride-rich lipoproteins named chylomicrons. The 
chylomicrons are rapidly hydrolyzed, releasing FFA for fuel, or deposited and leaving 
excessive surface components to produce nascent HDL. The endogenous lipoprotein 
pathway includes triglycerides and cholesterol synthesized by the liver, released to the 
circulation into large, triglyceride-rich VLDL, rapidly hydrolyzed (releasing FFA) and 
transformed into intermediate-density lipoprotein (IDL) and eventually LDL. The 
density increases in parallel with the depletion of triglycerides and increase of the 
cholesterol content. The structure of each lipoprotein resembles that of VLDL as 
depicted in Figure 1.1. 
.  
Ref.: www.medscape.com
Brunzell JD and Failor A. 
Metabolism (chapter), Diagnosis 
and Treatment of Dyslipidemia 
(section), in ACP Medicine, Dale 
DC and Federman DD (Editors), 
Web.MD (Publisher), New York, 
2006.  
Figure 1.1 Lipoproteins  
Copied according to a permission 
contract with Tiberah Berhanu, 
Permissions Editor in WebMD 
Corporation, the 30th of January 
2007. 
The lipoprotein shell is characterized by different apolipoproteins. They serve to 
activate surface receptors and enzymes essential for the uptake and metabolism of 
lipoproteins. Measuring apolipoprotein concentrations may have predictive value 
regarding cardiovascular disease for those apolipoproteins that are lipoprotein specific 
(but not for those who are not). 
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Similar to chylomicrons, also the catabolism of VLDL leaves excessive surface 
components to be used in the nascent HDL production. Nascent HDL is poor in 
cholesterol esters and can accept free cholesterol from various cells forming the large 
HDL (HDL2), which deliver cholesterol to the liver. Increased levels of the large HDL2 
reflect effective catabolism of triglycerides, such catabolism being important in 
preventing LDL- cholesterol from ending up in endothelial cells; thus large HDL2 are 
cardioprotective. Table 1.1 gives details of the composition of the main lipoproteins.  
 
Table 1.1 Composition of the major lipoprotein complexes 
 
Complex Source Density (g/ml) %Protein %TG
a %PLb %CEc %Cd %FFAe
Chylomicron Intestine <0.95 1-2 85-88 8 3 1 0 
VLDL Liver 0.95-1.006 7-10 50-55 18-20 12-15 8-10 1 
IDL VLDL 1.006-1.019 10-12 25-30 25-27 32-35 8-10 1 
LDL VLDL 1.019-1.063 20-22 10-15 20-28 37-48 8-10 1 
*HDL2
Intestine, liver 
(chylomicrons 
and VLDLs)  
1.063-
1.125 33-35 5-15 32-43 20-30 5-10 0 
*HDL3
Intestine, liver 
(chylomicrons 
and VLDLs)  
1.125-
1.210 55-57 3-13 26-46 15-30 2-6 6 
Albumin-
FFA 
Adipose 
tissue >1.281 99 0 0 0 0 100 
aTriacylglycerols, bPhospholipids, cCholesteryl esters, dFree cholesterol, eFree fatty acids *HDL2 
and HDL3 derived from nascent HDL as a result of the acquisition of cholesteryl esters. 
Ref.:  http://www.med.unibs.it/~marchesi/lipoprot.html. The table is last updated 5.11.2002 and copied with 
permission from prof. Sergio Marchesini the 26th of January 2007 under the conditions to be used for 
educational purposes and may not be duplicated in any form for commercial purposes.  
 
Dyslipidemia. The dyslipidemia in type 2 diabetes is characterized by 
hypertriglyceridemia, low concentrations of HDL cholesterol but almost normal 
concentrations of total cholesterol and LDL cholesterol [17]. The major abnormality is 
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elevation of VLDL (plasma triglyceride) due to its over-production and/or defective 
removal, contributing to an atherogenic lipoprotein phenotype with an atherogenic 
potential [18]. When less nascent HDL is produced, less cholesterol from LDL is 
transported to the liver. The endothelial cells of blood vessels have affinity for LDL, 
and cholesterol from LDL can enter the cells and damage the wall of the medium and 
large arteries. Another consequence of the elevated VLDL is the triglyceride enrichment 
of both HDL and LDL particles. This makes them a better substrate for hepatic lipase, 
which hydrolyses the triglycerides and makes HDL and LDL particles smaller and 
denser. Small dense LDL, typical for the dyslipoproteinemia in type 2 diabetes [19], is 
considered to be the most atherogenic among subclasses of lipoproteins [18]. Also the 
enlargement of the VLDL is suggested to be atherogenic [20]. When the HDL particle 
cores are loaded with triglycerides, these particles are broken down faster than normal 
HDL, which leads to a lower number of circulating total HDL (HDL particles) [21].  
Measuring lipoprotein qualities. Measuring total plasma cholesterol to predict 
cardiovascular risk can obscure the contributions of different atherogenic or 
cardioprotective lipoprotein particles [22], since all lipoproteins contain cholesterol 
(Table 1.1). Quantifying individual lipoproteins by measuring their cholesterol contents 
also has limitations, since the cholesterol (and triglyceride) content of LDL, HDL and 
VLDL particles is not constant. Several reports indicate that the numbers and/or size of 
separate lipoproteins, rather than their cholesterol content, are associated with 
cardiovascular risk or events [23-26], or with the metabolic syndrome [27], insulin 
resistance [28] or type 2 diabetes [29,30]. Thus, the lipoprotein particle numbers and 
sizes may be clinically important [31]. Direct assessment of lipoprotein particle 
numbers was not possible until the advent of nuclear magnetic resonance (NMR) 
spectroscopic analysis [32,33]. This analysis is based on lipoproteins having magnetic 
properties that give them a “bell-like” behavior that produces a signal that can be 
recorded by NMR (Figure 1.2). 
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Figure 1.2  
Lipoprotein subclasses 
behave like bells in the 
NMR anlyzer  
Ref.: www.liposcience.com 
(Otvos,JD 2002 [22], 
measuring 6 different VLDL 
subclasses; IDL, 3 LDL and 5 
HDL subclasses). 
The figure is copied with 
permission of dr. Jim Otvos the 
24th of January 2007. 
The orientation order of the phospholipids in the lipoprotein shell (Figure 1.1) induces 
differences in magnetic susceptibility for lipoprotein particles of different size [34]. The 
equations describing this effect predict that every lipoprotein particle with a different 
diameter should have a different NMR signature. Neither the apolipoproteins in the 
shell nor the distribution between triglycerides and cholesterol in the core are decisive 
for the lipoprotein diameter and the NMR signal, thereby making it possible to measure 
the “pure” size and particle number concentration of each lipoprotein subclass, as 
illustrated in Figure 1.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3  
Lipoprotein subclasses 
nomenclature and size  
Ref.: Otvos,JD 2002 
[22], measuring 6 
different VLDL 
subclasses; IDL, 3 LDL 
and 5 HDL subclasses. 
The figure is copied with 
permission of dr. Jim 
Otvos the 24th of January 
2007. 
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Oxidative products. Oxidative stress is associated with adiposity and insulin resistance 
in men [35]. Oxidative stress can be measured (indirectly) in many ways, such as levels 
of circulating oxidized LDL and isoprostanes. Oxidized LDL is found in monocyte-
derived macrophages in atherosclerotic lesions [36,37] but not in healthy arteries [38]. 
Small, dense LDL particles typical of type 2 diabetes penetrate more easily than native 
LDL into the sub-endothelial space of the vessel walls where the oxidative 
modifications take place [39]. Circulating oxidized LDL are reported to associate with 
risk factors of the metabolic syndrome in middle-aged men [40], and are elevated in 
patients with coronary heart disease [41,42]. 
Isoprostanes are considered to be reliable biomarkers of oxidative stress [43] since they 
are relatively stable and found in most tissues and fluids [44,45].They are converted 
non-enzymatically by the free radical-catalyzed peroxidation of arachidonic acid. The 
major F2-isoprostane (8-Iso-prostaglandin F2α) can be measured in both plasma and 
urine [46]. Isoprostanes may participate in pathophysiological processes by causing 
vaso- and bronchial constriction due to their ability to alter smooth muscle and platelet 
function [47]. 
1.2.6 Adipocyte hormones 
Adiponectin and leptin are hormones produced by adipocytes. Subjects with type 2 
diabetes, with impaired glucose tolerance or obesity without diabetes have lower levels 
of adiponectin compared with subjects not belonging to these categories. It is suggested 
that the positive correlation between adiponectin and insulin sensitivity [48,49] is linked 
to increased fat oxidation [50], and it is also proposed that adiponectin has anti-
inflammatory and anti-atherogenic properties [50]. 
Circulating leptin concentrations are reported to be proportional to total body fat mass 
and therefore elevated in obese subjects and in subjects with type 2 diabetes [51]. It is 
unclear whether leptin improves or inhibits insulin sensitivity [52,53]. Thus both 
adiponectin and leptin have the potential to influence the phenotype of type 2 diabetes; 
these hormones were therefore measured in this thesis. 
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1.3 Marine n-3 fatty acids 
Marine n-3 fatty acids (also named very long chain n-3 polyunsaturated fatty acids or 
omega-3 fatty acids) are the main part of the n-3 fatty acid family. The plant derived 
alpha-linolenic acid (18:3n-3) is the essential precursor of the n-3 fatty acid family. 
Linoleic acid (18:2n-6) is the essential precursor of the n-6 fatty acid family. These two  
fatty acids need to be provided by the food since the human organism lacks the enzymes 
capable of introducing double-bonds in the n-3 and n-6 positions of oleic acid (18:1n-9). 
Both n-3 and n-6 fatty acids use the same elongases and desaturases for further 
metabolism in the organism. The n-3 and n-6 fatty acids compete for the same enzymes, 
hence  the  balance between n-6 and n-3 fatty acids in the diet is important [54]. Marine 
n-3 fatty acids are produced by marine phytoplanctons, which accumulate in the food 
chain. The following marine n-3 fatty acids are therefore abundant in fatty fish, fish oils 
and sea mammals: 20:5n-3 (eicosapentaenoic acid (EPA)); 22:5n-3 (docosapentaenoic 
acid (DPA)) and 22:6n-3 (docosahexaenoic acid (DHA)). The 20:5n-3 and 22:5n-3, and 
to a limited extent, 22:6n-3, are formed from 18:3n-3 in humans. Marine n-3 fatty acids 
are reported to be twice as efficient as 18:3n-3 to reverse alpha-linolenic acid deficiency 
[55]. 
Both n-6 and n-3 fatty acids are important structural components of cell membranes, 
essential for various functions as fluidity, permeability, activity of membrane-bound 
enzymes and receptors, and for signal transduction [54]. In observational studies in the 
general population, consumption of moderate amounts fish or n-3 fatty acids from fish 
oil correlates with a lower risk of fatal coronary heart disease, in particular sudden 
cardiac death [56-62] via anti-arrhythmic effects [57,63]. A few secondary trials have 
been performed [64-66]; they report prevention of mortality due to CHD in patients 
with prior myocardial infarction.  
It is obvious that effects of n-3 fatty acids are multi-faceted and may differ between 
humans, depending, for instance, on the absence or presence of diabetes and/or 
dyslipidemia. More studies are needed to clearly delineate the effects of n-3 fatty acids 
in relation to specific diseases or types of metabolic dysfunction.  
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1.4 Dietary fat quantity and quality in type 2 diabetes 
1.4.1 Nutritional recommendations.  
In health and type 2 diabetes. The Norwegian recommendations of macronutrient 
distribution prevailing the population in general [67], are based on the Nordic Nutrition 
recommendations [54]. Fat should provide 25-35 % of the total energy intake (E%), 
carbohydrates (exclusive fiber) 50-60 E% and protein 10-20 E%. Regarding fat quality, 
saturated (SFA) plus trans fatty acids should be limited to approximately 10 E%, cis-
monounsaturated fatty acids (MUFA) 10-15 E% and polyunsaturated fatty acids 
(PUFA) 5-10 E%, including not less than 3 E% from essential PUFA (n-6 and n-3 fatty 
acids) and minimum 0.5 E% (preferably 1 E%) from the n-3 fatty acids in particular 
[67]. In Norway, subjects with type 2 diabetes are recommended the same food intake 
as to the population in general [68]. These guidelines are in accordance with the 
European ones [69], with exception of the encouragement to supplement the diet with 
cod liver oil (or other n-3 fatty acid supplements). In Europe there is no consensus on 
the use of supplements containing n-3 fatty acids in diabetes [69].  
The Nordic recommendation of a minimal intake of 0.5 E% n-3 fatty acids includes all 
n-3 fatty acids. There are no specific recommendations on the intake of marine n-3 fatty 
acids separated from the sum of 18:3n-3 fatty acids. Reference energy requirements for 
women (74-31 y) are 1700-2300 kcal/d, ranging from sedentary to physically active, 
and the corresponding requirements for men are 2200-3300 kcal/d [54]. When adjusted 
to the lowest and highest energy requirements respectively, the sum of all n-3 fatty acids 
should thus vary from 0.9 to 1.8 g/d. The American guidelines include at least 2 
servings/week of fish high in EPA and DHA ( in sum ~ 230 g fish), which provide at 
least 0.5 g/d of EPA and/or DHA [70]. As a comparison, Norwegian 5 ml/d cod liver oil 
or 3 servings/week of fatty fish contribute with ~ 1 g/d marine n-3 fatty acids. 
To summarize, subjects with type 2 diabetes are in general encouraged to increase the 
intake of dietary n-3 fatty acids in line with current recommendations for the general 
population. Also, available data are considered insufficient to make specific 
recommendations regarding the optimal ratio of dietary n-6/n-3 fatty acids [69]. 
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In hospitalized patients. Surgical stress stimulates counter-regulatory hormone 
secretion, which in turn decreases insulin sensitivity and inhibits insulin release [71]. 
These changes are diabetogenic and favor catabolism. From the nutritional point of 
view, special efforts are needed to achieve energy and protein balance in surgical 
patients, patients with type 2 diabetes included. The optimal distribution between 
carbohydrate, fat and protein in parenteral nutrition has been discussed for a long time 
and recommendations on fat quantity have been given. For example, it has been 
recommended  to infuse 2 g fat/kg/24 h, which covers 40 % of the basal energy 
requirement and ≥ 0.1 g/kg/24h 18:2n-6 fatty acid in order to avoid linoleic acid 
deficiency [72]. It has indeed been proposed to increase the content of n-3 fatty acids in 
parenteral nutrition [73]. 
Among hospitalized patients ~ 10 % have diabetes [74]. Among the heterogenic group 
of patients which needs parenteral nutrition, as many as 30% may have diabetes [75] . 
However, there appears to be no specific recommendations on the administration of n-3 
fatty acids to hospitalized patients with type 2 diabetes. 
Amounts of n-3 fatty acids in intervention and treatment. Previously 2-10 g/d of 
long-chain n-3 fatty acids have been used as supplements in intervention studies [76]. 
For long-term use, however, the US Food and Drug Administration (FDA) recommends 
9 g/d natural fish oil (18% EPA, 12% DHA) as upper limit [77], based on the 
recommendation of  3 g/d of marine n-3 fatty acids as upper limit from Menhaden oil 
[78]. FDA does not claim that a higher intake poses a health hazard and there are indeed 
data from traditional Greenland Inuits, indicating that a high intake throughout life (8.5 
g/d and up to ≥14 g/d of marine n-3 fatty acids [79,80]) is without apparent ill effects. 
When n-3 fatty acids are used as treatment of severe hypertriglyceridemia, the upper 
limit recommended by FDA may be passed since the only registered preparation in 
Norway (Omacor, (Pharmacia&Upjohn)) is recommended in intakes of 1.7-3.4 g/d 
initially, and increased to 5 g/d if not effective at lower dosage [81].  
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1.4.2 The impact of fat quantity and quality on phenotypes of type 2 
diabetes 
Glycemic control. A low-fat/high carbohydrate (but low fiber) diet compared with a 
fat-modified diet (high in MUFA) is reported to increase postprandial glucose and 
reduce insulin sensitivity in subjects with type 2 diabetes [82]. Opposite results were 
obtained, i.e. a decrease in postprandial glucose and insulin resistance, when adding 
fiber-rich foods (especially soluble fibers from legumes, fruit and vegetables) to the 
low-fat diet [82]. The latter results are, however, not clearly confirmed by others 
[83,84]. 
Effects of n-3 fatty acids on glycemic control and insulin sensitivity in type 2 diabetes 
are equivocal. Deterioration of glycemic control has been found in some [85-90], but 
not in all studies [91-100]. However, none of the controlled intervention studies in 
subjects with type 2 diabetes found better insulin sensitivity after supplementation with 
n-3 fatty acids [93,100,101]. In healthy subjects (the KANWU study) the improvement 
of insulin sensitivity achieved by a high MUFA diet was not affected by adding marine 
n-3 fatty acids [102]. 
Neither the clinical relevance of low-fat studies nor the effects of n-3 fatty acids on 
glycemic control have been completely elucidated in subjects with type 2 diabetes. In 
particular, few studies have investigated both effects on insulin resistance and insulin 
secretion per se. Also knowledge of the impact of parenteral administration of n-3 fatty 
acids to subjects with type 2 diabetes is lacking. 
Energy metabolism. A low-fat diet is reported to reduce EPR in morbidly obese 
subjects [103], however, this effect may be secondary to rapid weight loss. Different 
fatty acids are taken up and oxidized at different rates [104]. In theory, thus, increasing 
the proportion of n-3 fatty acids relative to other fatty acids could alter energy 
metabolism. Data on this subject are scarce in humans and subjects with type 2 diabetes. 
A small study in healthy humans reported a lower RQ (= increased fat oxidation) but no 
change in EPR after 3 wk intervention with 1.8 g marine n-3 fatty acids [105]. On the 
other hand  intervention with 3.8 g of n-3 fatty acids for 6 wk in subjects with type 2 
diabetes did not affect EPR or RQ [106]. The influence of marine n-3 fatty acids on 
energy metabolism in type 2 diabetes is largely unexplored.  
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Dyslipidemia. Marine n-3 fatty acids can reduce plasma triglycerides in 
hypertriglyceridemic subjects due to a reduced release of chylomicrons and VLDL 
[107]. Large doses (>3 g/d EPA+DHA) are reported to be necessary to lower 
triglycerides and VLDL cholesterol in non-diabetic [108], and diabetic [109,110] 
subjects, but doses < 2 g/d are also reported to be effective in type 2 diabetes [111]. 
Total cholesterol is not influenced by n-3 fatty acids [76]. As to effects on LDL 
cholesterol some studies report increased levels in type 2 diabetes [76,110], whereas 
others report tendencies for an increase [109,112], or no effects [113]. As to HDL 
cholesterol levels, these are reported to be increased by fish oil supplements in healthy 
subjects [114,115], but no effects were found in subjects with hypertriglyceridemia 
and/or type 2 diabetes [108-110,114].  
In type 2 diabetes effects of n-3 fatty acids on lipoprotein subclasses by standard 
methods have so far given diverging results [113,116,117]. Intervention studies on 
lipoprotein subclasses measured by NMR in type 2 diabetes have, to our knowledge, so 
far not been performed. A controlled study of effects on lipoprotein subclass qualities   
by marine n-3 fatty acid intervention measured by NMR seems warranted in subjects 
with type 2 diabetes.  
Oxidative products. In subjects with hypertension 3.4 g/d of marine n-3 fatty acids 
resulted in an increase of oxidized LDL [118]. In the KANWU study 2.4 g/d of marine 
n-3 fatty acids brought about a decrease in the non-enzymatic derived markers of 
oxidative stress (isoprostanes) in healthy subjects [38]. In diabetes there is little 
information on effects of n-3 fatty acids on oxidized LDL and isoprostanes, acutely and 
over time.  
Adipocyte hormones. It is hard to find studies reporting effects on adipocyte hormones 
by fat reduction, in which concomitant weight reduction is not a confounding factor.  
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 2. Aims 
 
The overall aim was to investigate specific effects of changing the intake of fat quantity 
and/or quality in subjects with type 2 diabetes. Specifically I wanted to test  
1. whether and to which extent a short-term (3 d) dietary intervention low-fat diet 
would affect glycemic control, lipids and hormones  (Paper I) 
2. whether and to which extent  a long-term (9 wk) marine n-3 fatty acid 
supplementation (fish oil) would affect blood glucose, insulin sensitivity, insulin 
secretion and energy metabolism in subjects with type 2 diabetes and 
normotriglyceridemia (Paper II) 
3. whether the same long-term intervention with n-3 fatty acids would affect 
lipoprotein size and subclasses and, if so, whether changes would relate to 
effects on insulin sensitivity (Paper III)  
4. whether an acute (4 h) infusion of marine n-3 fatty acids would affect insulin 
sensitivity, insulin secretion, adipocyte hormones, energy metabolism and 
oxidative products in subjects with type 2 diabetes and normotriglyceridemia 
(Paper IV).  
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3. Subjects and methods 
For Paper I, pre-screening of patients was based on information in medical records. 
Criteria for inclusion were primarily set for a study protocol in which fatty acids were 
acutely lowered by Acipimox [119]. The low-fat intervention was initially a part of this 
study. Subjects thought to be eligible (n=61), were sent a letter with the information that 
they would be contacted by telephone. The following telephone call was made in order 
to acquire acceptance or not to send a second letter to the patients with detailed 
information and an invitation to participate in the study. The offer to participate was 
accepted by 42 persons. After screening and inclusion 21 subjects participated in the 
Acipimox study [119] and 19 of these also in the low-fat study reported in Paper I 
(Figure 3.1). Following the initial part of the study (after inclusion, Figure 3.1), the 
participants recorded - for the second time - their food intake by weighing their usual 
diet for 3 d (followed by measurements of fasting variables). Then they were instructed 
to go on living as usual for the next 2-3 wk until the 3 d of low-fat diet. To ensure a 
setting of free living the composition of the low-fat diet was given in general 
An overview of study populations, design, interventions, endpoints and time-course is 
given in Table 3.1. Further details of the design are given in the flow diagrams of Figure 
3.1.  
All studies were carried out at St. Olavs Hospital, Trondheim in the Department of 
Medicine, Division of Endocrinology. The low fat study (Paper 1) was carried out 
October the 28th 1997 to October the 20th 1998. Study subjects for this study were 
recruited from patients treated at the diabetes out-patient clinic of the Division of 
Endocrinology.  In the other two studies (Papers II-IV) study subjects were recruited 
from the primary health care. These later studies were performed from October the 1st 
2001 to December the 17th 2002 (n-3 supplement study, Papers II and III) and from 
January the 9th to May 13th 2004 (n-3 infusion study, Paper IV). 
3.1 Study populations and design 
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The degree to which blinding was achieved, was evaluated by a post-study 
questionnaire (Appendix A) in which subjects were asked which oil (Photo 3.1) they 
thought they had ingested (details on the procedure are given in Paper II). As to the 
blinding of investigators, all analyses were performed before the randomization code 
was broken.  
The discrepancy between the number of subjects willing to participate in the n-3 fatty 
acid intervention studies on one hand and those passing the screening criteria on the 
other (Figure 3.1), was due to stringent exclusion criteria, (such as smoking and regular 
use of supplements with marine n-3 fatty acids) which could not readily be formulated 
in an advertisement. Responders to the advertisement had the opportunity to cut 
smoking for ≥ 3 months or/and accept a wash-out period of n-3 supplements for ≥ 6 
months. Many then declined participation.  
In the n-3 supplement study the pre-screening process had fewer stages, since subjects 
who were eligible for participation had already expressed their willingness to participate 
by responding to an advertisement.  
but concrete terms (written and orally). The study subjects also measured their blood 
glucose 5 times daily and recorded quantity and quality of physical activity during each 
day of dietary recording.  
 
Photo 3.1  
 
Study oils in the n-3 supplement study  
 
Corn oil and fish oil flavored with lemon 
were distributed in liquid form in identical 
bottles. The subjects received disposable 
premarked 20-mL dose cups.  
 
Photo taken by ILM, 2002. 
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For the n-3 infusion study (Paper IV), the procedure from advertising to inclusion was 
similar to the n-3 supplement study (Figure 3.1), as was also the clinical characteristics 
of the study population (Table 3.1). Included were subjects with appropriate veins for a 
4-hour long infusion period. By this criterion we had to exclude some subjects. Subjects 
with hypertriglyceridemia were excluded because of our concerns about the lipid-
increasing effects of the fat infusion (~ 80 g), given during 4 h. The same concerns 
resulted in that the meal served after each clamp was low-fat. Furthermore, the subjects 
were told to avoid intake of fat for the rest of that particular day. 
 
3.2 Measurements 
3.2.1 General  
Taken all studies together, most endpoints are common (Table 3.1). The methods for 
each of them are presented in Table 3.2. Table 3.2 also gives an overview of other 
measurements (food intake, body composition and fatty acids, physical activity, 
compliance to the interventions and blinding).  
3.2.2 Glycemic control 
Fasting blood glucose. Venous blood serum samples after 12 h of fasting were 
analyzed in the Department of Medical Biochemistry (St. Olavs Hospital) on each day 
of testing. On the same days we also analyzed concentrations of fasting blood glucose 
with the YSI Glucose Analyzer in venous whole blood samples, which were drawn at 0 
min of the clamps (Papers II and IV). Glucose values obtained from these whole blood 
sample values were – expectedly - lower (13-15%) than values obtained in serum. In 
addition, the study subjects measured fasting blood glucose themselves at home (in 
capillary whole blood), during both the low fat and the n-3 supplement studies (Papers I 
and II-III).  
Day-time blood glucose. In the low-fat study (Paper I), subjects measured day-time 
blood glucose (capillary whole blood) 5 times a day (fasting, pre-lunch, pre-dinner, 2 h 
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after dinner, at bedtime) during the 3 d periods of dietary recording, using their own 
glucose measuring devices. In the n-3 supplement study (Papers II and III) all subjects 
used the same glucose measuring device (details in Paper II). For Paper I the values 
were recorded in the dietary recording form (Appendix B) and for Paper II in a separate 
blood glucose measurement form (Appendix C). 
HbA1c (glycated hemoglobin). In all studies subjects measured HbA1c at baseline. 
HbA1c was also measured after 9 wk intervention in the n-3 supplement study. 
Insulin sensitivity. In the low-fat study (Paper I), insulin sensitivity was assessed as the 
ratio between fasting glucose (mg/L) and insulin (mU/L) [120,121]. For the n-3 
intervention studies (Papers II - IV) we used isoglycemic hyperinsulinemic clamps. As 
others [122], we preferred  isoglycemic to euglycemic clamps since we then could study 
the diabetic subjects in their native (hyperglycemic) conditions and avoid the 
confounding effect of insulin preinfusion (to achieve euglycemia). Subjects were thus 
clamped at the level of fasting glucose as measured the day of the baseline clamp. In the 
n-3 supplement study (Papers II and III) the clamp duration was 2 h and the insulin 
infusion 40 mU/min/m2. Insulin sensitivity was assessed by glucose utilization, i.e. the 
amount of glucose (mg/min/kg lean body mass (LBM)) that was infused in order to 
maintain the fasting glucose concentration during the last 40 min of each clamp. In the 
n-3 infusion study (Paper IV), a higher rate of insulin infusion was chosen (80 
mU/min/m2) because we expected insulin resistance to progress during the infusion due 
to the co-infusion of lipid with glucose. These clamps lasted for 4 h in order to reach 
steady state. Again glucose utilization during the last 40 min was used to calculate 
insulin sensitivity. 
Insulin secretion. In the low-fat study, fasting levels of insulin and glucose were used 
to assess insulin secretion. We calculated HOMA (Homeostatic Model Assessment) for 
β-cell function (20 x insulin mU/L / (glucose mmol/L – 3.5) as published [121,123].  
In the n-3 supplement study, insulin secretion was assessed in the fasting mode by a C-
peptide glucagon test [124,125]. This test is a long term validated one for assessing 
insulin secretion [126]. We performed the test on the day preceding a day of clamping. 
We considered potential variation in the response time to reach the maximum level of 
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C-peptide. Therefore we added measurements to include the time points 5, 6 and 7 min 
after the injection of glucagon. The maximum increment in C-peptide concentration 
obtained during min 5-7 was used for calculations.  
In the n-3 infusion study we modified the standard C-peptide-glucagon test in so far that 
the test was performed not fasting but instead 15 min after end of the 4 h clamp.  
3.2.3 Energy metabolism  
EPR. Basal EPR (kcal/24 h) was measured by indirect calorimetry during 0 min in the 
resting mode after 12 h fasting. We performed indirect calorimetry measurements with a 
closed ventilated hood system (Photo 3.2) at baseline, and after 1 and 9 wk of 
intervention in the n-3 supplement study. Measurements were performed both in the 
fasted state and during clamps (Paper II). In the n-3 infusion study indirect calorimetry 
was measured during all clamps and additionally in the fasted state, but then only at 
baseline (Paper IV). 
 
 
Photo 3.2  
 
Indirect calorimetry in the 
resting mode 
 
(Papers II and IV)  
 
 
 
 
 
Photo taken by ILM and 
authorized by the subject, 
2002.  
Dietary macronutrient composition is associated with predictable rates of O2 
consumption and CO2 production, while urinary nitrogen excretion rate reflects protein 
oxidation rates. From this information, energy expenditure is calculated from specific 
equations [13,127,128]. The conversion factors for carbohydrate, fat and protein in 
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terms of kcal/g are somewhat higher for indirect calorimetry (4.18, 9.46 and 4.32) than 
those used for food (4, 9, 4), [128] .  
In the low-fat study, baseline BMR was calculated according to the equations given in 
Table 3.3.  
Table 3.3 BMR calculated on the basis of gender, age and weight  
GENDER AGE, y BMR (kcal/24 h) 
women 30-59  8.7 x kga – 25 x  mb + 865 
women 60+ 9.2 x kg + 637 x  m – 302 
men 30-59 11.3 x kg + 16 x  m + 901 
men 60+ 8.8 x kg + 1128 x  m – 1071 
a bm, measured to two decimal points [14]. kg, measured to one decimal point; 
 
RQ. When indirect calorimetry measures the respiratory gas exchange to estimate the 
rates of fat and carbohydrate oxidation, a stable protein oxidation is assumed, which is 
usually set to 81 g/d or 13 g/d nitrogen in  the urine [128,129]. We sampled urine for 9 h 
during the night before fasting measurements of indirect calorimetry in the n-3 
supplement study. Therefore we could calculate the urinary loss of g nitrogen (x 6.25=g 
protein metabolized, adjusted to 24 h). We used that information to calculate the non-
protein RQ (details in Paper II).  
3.2.4 Lipid variables 
Fasting plasma lipids (triglyceride, total cholesterol) were measured at baseline and 
after interventions in all 3 study protocols. Lipoprotein lipids (HDL cholesterol, LDL 
cholesterol) were measured or calculated at the same occasions, with the exception of 
LDL cholesterol, which was not calculated in the hypertriglyceridemic subjects in the 
low-fat study (Paper I), since Friedewalds formula (Cholesterol – HDL cholesterol –  
0.46 x triglycerides) can only be used when triglycerides are ≤4.0 mmol/L [130]. 
To avoid in vitro lipolysis, the samples to be used for analyzing free fatty acids were 
drawn into EDTA-containing tubes and handled quickly. In the n-3 infusion study 
duplicate samples (EDTA plasma) for all subjects were also analyzed at a second 
laboratory (Uppsala) in order to compare values analyzed at the Department of Medical 
Biochemistry at St. Olavs Hospital (Paper IV). 
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NMR measurements for lipoprotein subclasses were performed in the overnight fasted 
state at baseline, at 1 and at 9 wk of intervention in the n-3 supplement study (Paper III).  
Oxidized LDL was measured (Paper III) using a standard method (Oxidized LDL 
competitive enzyme linked immunoabsorbent assay), as described [41,42]. Isoprostanes 
in plasma and urine were measured by a specific radioimmunoassay in the n-3 infusion 
study (Paper IV) [46]. 
3.2.5 Body composition 
In the n-3 studies Dual energy X-ray Absorptiometry (DXA) scanning (Photo 3.3) was 
used to measure lean, fat and total body mass at baseline and also after 9 wk 
intervention in the n-3 supplement study. Insulin sensitivity (glucose utilization) and 
EPR is expressed relative to LBM in those studies, since we tried to avoid the 
confounding factor of different distribution between fat and LBM in men compared 
with women. 
Photo 3.3  
 
DXA scanning  
 
 
 
 
 
 
 
Photo taken by ILM and 
authorized by the subject, 
2002. 
 
3.2.6 Dietary intake 
Retrospective method. To assess energy and nutrient intake at baseline a Food 
Frequency Questionnaire (FFQ) for about 180 food items was used (Appendix D). The 
same FFQ was used in all studies (Table 3.2). This retrospective questionnaire is self-
administered. It was sent by mail to the participants to be filled out at home. At baseline 
the filled-out questionnaire was checked during a personal interview (ILM) to eliminate 
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inconsistencies, misunderstandings and errors. The results were computed by using a 
food database (AKF96) and software systems (BEREGN) developed at the Department 
of Nutrition Research, University of Oslo. The food database was mainly based on the 
official Norwegian food table [131]. The analysis of the FFQs filled in by the 
participants in the low-fat study during 1997-1998 has not been published except in the 
present thesis (in the chapter of Results). When the Department of Nutrition Research 
evaluated these FFQs in 1998 they could not guarantee the validity of results of energy 
intake from the main groups of fatty acids since the composition of margarines in the 
database were updated only until 1995, whereas margarine factories in Norway 
frequently changed the composition of margarine during the time period of the low-fat 
study (1997-98). Since margarine is a main ingredient in cooking this uncertainty 
influenced the information obtainable from the analyzed FFQs. These results in the 
present thesis should therefore be interpreted with caution. However, the FFQ fatty acid 
results of the both n-3 studies (Papers II and IV) are based on an updated version of the 
database, which includes reliable information on the composition of margarine in 
Norway at the time of performance of these studies (2001-2004). 
For all studies the sum of E% from SFA, MUFA, n-3 and n-6 or the sum of SFA, 
MUFA and PUFA are 3-4 E% lower than the calculated E% of total fat. This is because 
information of fat quality is missing for some food items. However, fat quantity 
information is never missing; thus, total fat intake was satisfactorily analyzed.  
Prospective methods. Food recording by weighing was the prospective method chosen 
in order to assess each subject’s usual and intervention diet in the low-fat study (Table 
3.2). The weighed records of the usual diet (Appendix B) supplemented the 
retrospective records obtained by FFQ. The weighed records were analyzed almost a 
year later than the FFQs. Only total fat content is published in Paper I and also here (in 
the Results section). Nevertheless we could estimate the main intake of marine n-3 fatty 
acids from consumption of several fatty fish varieties, and these results are given in the 
text of Paper I.  
Estimated records by household measures were the prospective method chosen to be 
carried out the day before each clamp in the n-3 infusion study (Table 3.2). The 
intention was to ensure similar food and beverage intake before the clamps since the 
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subjects were encouraged to eat the same food before the second clamp (Paper IV). 
Regarding the 1 day records, we had to use another database for nutrient analysis (Mat 
på data). This database gives the amounts of saturated, monounsaturated and 
polyunsaturated fatty acids, but does not calculate separate amounts of the n-6 and n-3 
fatty acids. 
3.2.7 Fatty acids in adipose tissue 
Our study introduced the biopsy procedure (Photo 3.4) at St. Olavs Hospital (Paper II), 
[132]. 
 
Photo 3.4  
 
Subcutaneous adipose tissue biopsy  
 
Adipose tissue was obtained from 
one buttock by needle aspiration. 
 
The specimen was placed on ice and 
frozen immediately at -80ºC, pending 
later analyses of the fatty acid 
composition. 
 
Photo taken by ILM and authorized 
by the subject, 2002.  
 
3.3 Statistics 
Statistical analyses were performed with SPSS versions 11.5 and 13.0 (SPSS Inc, 
Chicago, IL, 2003 and 2005). Assumptions of normality were checked by Shapiro-
Wilks’ test in Paper I and by visual inspection of normal Q-Q Plots in Papers II-IV. 
Randomization was performed by the method of minimization [133]. Results are given 
as median values and the variability as the interquartile range (IQR; the distance 
between the 75th and 25th percentile values) in text and the most tables in all Papers, and 
as means (variability as 95% CI or SEM) as indicated in some tables and figures. Table 
3.4 gives a brief overview of the methods of significance testing used. A P-value ≤0.05 
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(two-sided) was considered significant. Spearman’s correlation coefficients (r) were 
used to evaluate bivariate correlations. Statistical details are described in each Paper. 
 
Table 3.4 Statistical methods 
 Papers 
 I II III IV 
The paired  Wilcoxon signed ranks test x x  x 
The unpaired Mann-Whitney test x x x  
The independent samples t test  x   
ANCOVA, General linear model, Univariate procedure  x x  
ANOVA, General linear model, Repeated measures procedure  x x x 
Bonferroni adjustments  x   
For abbreviations, please refer to the abbreviation list. 
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4. Results  
 
4.1. General 
In Papers 1-IV results were generally presented as medians and inter-quartile ranges 
(IQR). In the following Results section of this thesis some main results are given as 
mean values and (95% CI).  
4.2 Baseline results 
4.2.1 Study subjects 
Baseline characteristics of all study participants are given in Table 4.1.  The subjects in 
the low-fat study were more overweight and their glycemic control and lipid profile was 
more abnormal compared with the participants in the other two studies. The n-3 fatty 
acid relative concentration of plasma phospholipids expressed as weight% was ~ 13 
g/100 g in the low-fat study compared with 9-10 g/100 g in the n-3 studies (Table 4. 1). 
Among the 19 subjects of the low-fat study 5 were regular users of n-3 fatty acid 
supplements. The use of supplements corresponded with an increased n-3 fatty acid 
weight% to ≥15 g/100g plasma phospholipid fatty acids (not published in Paper I). The 
concentrations of total plasma phospholipid fatty acids correlated positively to the 
triglyceride concentrations in all studies but significantly only among the 
hypertriglyceridemic subjects in the low-fat study (r=0.691, P=0.001).  
4.2.2 Energy intake 
Baseline energy intake and macronutrient distribution are summarized for all three 
studies in Table 4.2. In the low-fat study, the FFQ and weighing records showed close 
agreement regarding total energy intake but discrepancy as to the energy distribution 
between carbohydrate, fat and alcohol. In the n-3 supplement study, baseline diet was 
recorded by FFQ only. In the n-3 infusion study, the total energy intake calculated from 
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FFQ differed from the 1 d estimated records by household measures but showed lesser 
discrepancy regarding the E% of carbohydrate and fat. A comparison of energy intake 
and distribution based on FFQ in all three studies shows (by eye-glance) somewhat 
lower energy intake in the n-3 supplement study compared with the others (Table 4.2).  
4.2.3 Energy expenditure and distribution  
Baseline resting energy expenditure (EPR or BMR) is given as kcal/24 h for all studies 
in Table 4.2. Results of the relative contribution of protein, fat and carbohydrate as fuels 
are also given for the n-3 studies (Table 4.2). The subjects of the n-3 supplement study 
displayed higher RQ than those of the n-3 infusion study.  
 
4.3 Endpoint results 
4.3.1 General 
An overview of endpoint fasting variables (Papers I, II and III) and endpoint test 
variables (Papers II and IV) is given in Table 4.3.  
4.3.2 Glycemic control 
In the low-fat study, the fasting blood glucose concentration was reduced (median – 0.4 
mmol/L, P=0.049) when measured at home, and also when measured in serum samples 
at hospital (-0.6 mmol/L, P=0.049), after 3 d intervention (Paper I). The day-time blood 
glucose was not affected. In the n-3 supplement study, 5.9 g/d of marine n-3 fatty acids 
increased fasting blood glucose by 1.0 mmol/L (P=0.035) and day-time concentrations 
by 0.9 mmol/L, after 9 wk intervention compared with corn oil (Paper II). Further the 
insulin sensitivity (glucose utilization) was reduced by 1.56 mg/min/kg lean body mass 
(P=0.049) when compared with corn oil (Paper II). There was a tendency to increased 
insulin secretion in response to glucagon in the fish oil group compared with the corn 
oil group, P=0.078 (Paper II). Neither insulin secretion nor insulin sensitivity were 
measurably affected by the low-fat (Paper I) or n-3 infusion (Paper IV) interventions, 
Table 4.3.  
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The clamp conditions regarding isoglycemia and hyperinsulinemia were comparable in 
the two groups of the n-3 supplement study (Figure 4.1). Also baseline fasting insulin 
and glucose concentrations were comparable- (Paper II). 
 
Figure 4.1 Hyperinsulinemic, isoglycemic clamps in the n-3 supplement study  
corn oil group (n=14), fish oil group (n=12).Mean values (and SEM, S-insulin) 
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4.3.3 Energy metabolism
 
In the n-3 supplement study. The resting EPR was stable from baseline to 1 and 9 wk 
(Paper II). The non-protein RQ was increased after 1 wk, followed by a decrease at 9 
wk in the fish oil group compared with the corn oil group (Figure 4. 2). That is, fat 
utilization as fuel was temporarily decreased after 1 wk (but NS), after which it was 
significantly increased with a concomitant decrease in carbohydrate utilization (Paper 
II). 
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Figure 4.2 Non-protein RQ before clamps at baseline, 1 and 9 wk, n=26 
■…■ Corn oil group 
▲___▲ Fish oil group 
  
Time x group effect analysed by the 
repeated measurements ANOVA. Means 
not sharing a common superscript letter are 
significantly different at P<0.05 (Bonferroni 
correction). 
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In the n-3 infusion study. EPR increased significantly during both lipid infusions 
compared with the fasting mode (Paper IV). However, EPR did not differ between the 
standard lipid infusion and the one to which n-3 fatty acids had been added.  The non-
protein RQ was lowered by the lipid infusions (i.e. they led to higher utilization of fat as 
fuel) compared with the glucose clamp. However, we found a tendency to higher non-
protein RQ, i.e. lower utilization of fat as fuel, during  the infusion with n-3 fatty acids 
compared with the standard lipid infusion, P=0.062 (Paper IV). In other words, the 
increase in fat oxidation compared to the fasting mode appeared less pronounced during 
the infusion with n-3 fatty acids. 
4.3.4 Variables of lipid metabolism.   
Plasma triglycerides were not affected by the low-fat diet (Paper I). However, total and 
HDL cholesterol were reduced with 0.4 (P<0.005) and 0.03 mmol/L (P<0.05), 
respectively. Plasma lipids or lipoprotein lipids were not influenced by the n-3 
supplement intervention (Paper III) or by the infusion of n-3 fatty acids (Paper IV).  
Fasting concentrations of FFA were not affected by the low-fat (Paper I) or the n-3 fatty 
acid intervention (Paper II). However, the reduction of FFA concentration brought 
about by insulin during hyperinsulinemic clamps was moderately antagonized after 9 
wk of intervention in the fish oil group compared with the corn oil group (Paper II). On 
the other hand the acute infusion of n-3 fatty acids tended to influence concentrations of 
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FFA by dampening the rise during lipid infusion. The mechanisms behind the latter 
effect are unclear (Paper IV). 
Lipoprotein size and subclasses were affected in several respects by the intervention of 
5.9 g marine n-3 fatty acids (Paper III, and summarized here in Table 4.4).  
Oxidized LDL was not significantly affected by fish oil compared with corn oil (Paper 
III). As to isoprostanes, the marked increase of plasma F -isoprostanes (8-iso-PGF2 2a) 
during lipid infusion was not modified when n-3 fatty acids were added to the standard 
lipid infusion (Paper IV). 
Table 4.4 Lipoprotein size and subclass particle concentrations at baseline, 1 and 9 wk, n=26 
1Repeated measurements analyses of variance for time (baseline, 1 wk, 9 wk) x group 
interaction; 2Analyses of covariance with the 9 wk measurements as the dependent variable and 
baseline measurement and group as covariates. For abbreviations, please refer to the 
abbreviation list. 
 
4.3.5 Adipocyte hormones. 
In the low-fat study (Paper I) the concentrations of fasting leptin decreased from 12.1 to 
9.9 ng/mL (P<0.005) after 3 d of low-fat diet compared to the usual diet. Levels of 
adiponectin increased from 8.6 to 10.5 μg/mL (P=0.048) (Paper I). These adipocyte 
 
Variables  
 
Corn oil group 
  
Fish oil group P-values 
  n=14  n=12     
1  mean 95% CI mean 95% CI ANOVA ANCOVA2
41.6 50.0 43.0 49.1 VLDL size, baseline nm 45.6 46.1   
41.7 47.8 38.2 44.7                        1 wk  44.7 41.5   
41.5 49.5 36.3 41.5                        9 wk  45.5 38.9 0.001 <0.001 
0.3 5.1 0.5 4.2 Large VLDL, baseline nmol/L 2.7 2.3   
 0.1 3.1 -0.6 2.9                       1 wk 1.6 1.1   
0.3 3.4 -0.3 1.0                       9 wk  1.8 0.3 0.041 0.015 
751 1212 685 1333 Small LDL, baseline nmol/L 982 1009   
719 1137 939 1298                       1 wk  928 1118   
821 1331 978 1564                       9 wk  1076 1271 0.068 0.061 
8.9 9.3 8.8 9.3 HDL size, baseline nm 9.1 9.0   
9.0 9.3 8.9 9.4                       1 wk  9.2 9.1   
8.8 9.2 8.9 9.4                       9 wk  9.0 9.1 0.063 0.033 
23.4 29.5 27.5 31.7 Total HDL, baseline μmol/L 26.4 29.6   
25.2 31.3 26.2 31.0                       1 wk  28.3 28.6   
24.8 30.9 25.6 31.8                       9 wk  27.9 28.7 0.044 0.269 
14.8 19.0 18.8 22.5 Small HDL, baseline μmol/L 16.9 20.6   
16.2 20.3 17.2 21.3                       1 wk  18.3 19.3   
16.3 21.0 15.9 21.0                       9 wk  18.7 18.5 0.004 0.051 
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hormones were not affected by n-3 fatty acid supplement (Paper II) or by the infusion of 
n-3 fatty acids (Paper IV). 
4.3.6 Fatty acids in plasma and adipose tissue 
The changes that we observed in fatty acid composition of plasma phospholipids 
indicated good compliance to the dietary intervention both in the low-fat study (Paper I) 
and the n-3 supplement study (Paper II, Supplemental Tables). The changes observed in 
the supplement study were in agreement with changes in fatty acids in subcutaneous 
adipose tissue, which was biopsied after 9 wk of intervention (Paper II). 
4.3.7 N-3 fatty acid infusion results 
Acute infusion of n-3 fatty acids added to a standard lipid infusion did not affect energy 
metabolism, levels of oxidative products (isoprostanes) or adipocyte hormones but, 
tended to reduce fat oxidation and dampen the lipid-induced rise in FFA (Paper IV). 
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 5. Discussion 
 
5.1 Methodological considerations 
5.1.1 Study populations and design 
All three study populations consisted of subjects with type 2 diabetes not treated with 
insulin and were well defined. Subjects of the low-fat study were less well controlled in 
terms of glycemia and lipid profile compared to the subjects of the other studies (Table 
4.1). This may be due to their hypertriglyceridemia, which was part of the design. 
Hypertriglyceridemic subjects were chosen for the low-fat study since we assumed that 
such dyslipidemic individuals had the most to gain from a low-fat diet. In the n-3 
supplementation study, subjects with normotriglyceridemia were chosen to avoid 
secondary effects on insulin resistance by the known ability of n-3 fatty acids to reduce 
hypertriglyceridemia. Since the n-3 infusion study was to some extent inspired by the 
results of the in-3 supplement study, we chose a study population that resembled the 
former.  
Subjects of the low-fat study had higher concentration of plasma phospholipid n-3 fatty 
acids than subjects in the n-3 fatty acids supplement study (Table 4.1). This difference 
indicates the importance of incorporating a wash-out period in studies concerning 
effects of n-3 fatty acids. Further, the above-mentioned differences seem to indirectly 
confirm that the use of n-3 fatty acid supplements (cod-liver oil, fish oil capsules) is 
widespread in Norway, as reported to prevail 35-40% of the population during winter 
[134,135]. It is interesting to note that the levels that we obtained were similar [136] to 
the reported ones in Inuits in the 1990s and higher than in Canadian native populations 
[137]. The choice of a long wash-out period (≥6 months) was based on previous 
observations that 2-4 [138,139] or 6 months [140] are necessary to presumably 
eliminate an influence of marine n-3 fatty acid supplementation on phospholipid 
composition. It follows that many cross-over studies in the field have used a too short 
wash-out period in between the cross-over periods. Still we estimate that 2 wk was 
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enough in our own cross-over study (Paper IV) because we used a single dose of n-3 
fatty acids only.  
When dealing with dietary oils the choice of placebo is not an easy one. The need for 
the placebo oil to be acceptable to Norwegian food habits motivated our choice of corn 
oil (Paper II). 
5.1.2 Measurements 
Insulin sensitivity. The need for glucose infusion to uphold a certain level of blood 
glucose depends both on glucose uptake and endogenous glucose production. 
Production (glucose output from the liver) is sensitive to insulin effects; therefore it 
should be possible in principle to infuse enough insulin to block glucose output 
completely. The insulin level during an euglycemic hyperinsulinemic clamp should be 
around 400 pmol/L in order to suppress glucose output from the liver [127], and we 
achieved 6-700 pmol/L and ~ 1000 pmol/L in the n-3 supplement respective infusion 
study. However, other investigators report the need of even higher insulin levels to 
insure blocking the glucose release from liver in insulin resistant subjects [141]. Thus, 
we cannot exclude the possibility that glucose utilization as measured here reflects both 
glucose uptake and production rather than glucose uptake alone. 
Lipid variables. Some studies fail to find good correlations between NMR 
measurements and the standardized, validated method of ultracentrifugation. That does 
not necessarily mean that the NMR method is invalid but rather that NMR measures 
other lipoprotein qualities than the cholesterol parts. Indeed, Packard CV et al argue that 
novel types of measurements (such as NMR) will provide insight into regulation of 
subfraction lipoprotein distribution [18]. 
Dietary intake. Using retrospective methods a disadvantage is that one depends on the 
subjects’ capacity to remember and generalize his/her mean intake of food. Using 
prospective methods you may instead interfere with the subjects’ food habits by the 
mere asking for continuous documentation. Clearly, then, there exists no perfect method 
of diet registration.  
In the low-fat study the intention was to check how the subjects translated general 
dietary principles (to reduce saturated fat, promote fibre-rich foods and unsaturated fat, 
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especially n-3 fatty acids) into concrete food choices. For that purpose we considered 
weighing to be the best method. We were somewhat surprised that energy intake 
reported from the weighed records was similar to the FFQ recording at baseline 
(because weighing usually underestimates [142,143], whereas FFQ records a higher 
energy intake compared with weighing [144-146]. Nevertheless, the method of FFQ is 
found to report lower E% from fat and higher E% from carbohydrate, compared with 
weighed records [144,147]. This discrepancy was also found in our study. 
The weighing method was not used in the protocol for the n-3 fatty acid supplement 
study, the reasons being that a) the intervention protocol was demanding on the 
participants and b) the FFQ performed at baseline and at the end of intervention were 
deemed sufficient to assess stability of food intake. 
As to the n-3 infusion study, the baseline FFQ was performed mostly to describe the 
subjects at baseline in the same manner as the other study subjects of this thesis. The 
choice of using household measures to estimate portions instead of weighing was to 
minimize the burden on the participants. However, the results demonstrated the 
difficulties in first describing food portions and then converting those descriptions to 
amounts in g. Therefore it was not a surprise the energy intake was reported as 
markedly lower by this method than by FFQ. All in all we consider the chosen dietary 
recording methods as appropriate for assessing diet during the study conditions. 
5.2 Main results 
5.2.1 Glycemic control 
We focus in Paper I on the fact that the day-time average blood glucose was not affected 
by the low-fat diet. However, in terms of glycemic control one should acknowledge that 
the fasting blood glucose was significantly decreased by the low-fat diet. It seems 
possible that a discrepancy between effects on day-time and fasting blood glucose levels 
could be caused by improved insulin sensitivity of the liver (i.e. reduced glucose 
production) and not to the same extent a reduction of glucose uptake by skeletal 
muscles. However, we did not perform trace experiments, such as with radioactive 
glucose and therefore have no hard data to support this notion. Also, the low-fat diet 
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was different from the usual diet not only with regard to quantity and quality of fats but 
also with regard to carbohydrates and led to a slight energy deficit. The reasons why the 
diet was positive for the fasting component of glycemic control may thus be multiple.  
All evidence indicates that the moderate increase in blood glucose levels by the 9 wk n-
3 fatty acid intervention (Paper II) was the result of increased insulin resistance and not 
reduced insulin secretion, as suggested elsewhere [86-88,90]. The improved glucose 
utilization in the control group is likely an unspecific effect of trial participation. In any 
case, I find it reasonable to state that secondary effects of weight reduction as 
confounder can be ruled out, since the subjects were weight stable throughout the entire 
9 wk of this study (Paper II). 
How important was the large dose of ~ 6 g/d n-3 fatty acids for the negative result on 
the glycemic control - and is such a dose clinically relevant? In spite of the high dose 
we observed only moderate effects on insulin sensitivity, suggesting that lower doses 
may have only marginal effects. However, we cannot be completely sure, since we did 
not perform a dose-response study.  
We deliberately chose a high dose of n-3 fatty acids for the following reasons. First, if 
beneficial rather than negative results had been found in our study, then n-3 fatty acids 
could be recommended to subjects with type 2 diabetes without restrictions on dosage. 
Second, for detection of possible effects a high dose would give us better possibilities to 
register effects (as was also apparent for insulin sensitivity measurements). Third, we 
thought that the use of a high dose would facilitate delineation of time-course effects. 
One may question whether one can tolerate a high dose (5-6 g/d) of n-3 fatty acids in a 
life-time perspective. Inuits have in the 1970s been reported to eat ~ 9 g /d [79], in the 
same period also intakes ~ 14 g/d/3000 kcal were reported [80], all without apparent 
negative effects of n-3 fatty acids [79]. From a medical point of view, doses up to 5-6 
g/day have been reported to be useful in treatment of hypertriglyceridemia and perhaps 
other pathological conditions. Hence, besides being helpful in a research perspective, 
the choice of a high dose on n-3 fatty acids in our study seems to be at least partly 
relevant in an epidemiological and clinical perspective. 
52 
Discussion 
However, the dose used here is far above the recommended intake of n-3 fatty acids of 
about 1 g/d to prevent cardiovascular disease in the general population. Furthermore, it 
was not our intention to extrapolate the present results in type 2 diabetic subjects to non-
diabetic subjects. In any case, the present results offer no justification for taking away 
the daily spoon of cod liver oil from the man in street!  
5.2.2 Energy metabolism 
Our results on n-3 effects on RQ (Paper II) appear not to have been reported before. The 
main finding was increased fatty acid oxidation at the end of the intervention. The 
mechanisms behind are not elucidated here. It has been proposed that n-3 fatty acids 
enhance fatty acid oxidation by utilization of PPAR receptors [107].  
We found a strong tendency for lowered fat oxidation after 1 wk of intervention with n-
3 fatty acids. This would mean that metabolic handling of n-3 fatty acids is 
characterized by some delay. It cannot be explained as inhibited fat oxidation due to 
energy surplus [148] since the diet was energy stable. We suggest in Paper II that the 
time-dependency of an increase in fatty acid utilization (taking at least more than 1 wk 
and less than 9 wk) indicates induction of enzymes essential for fatty acid mitochondrial 
or peroxisomal oxidation.  
5.2.3 Lipid variables 
Plasma and lipoprotein lipids. In the low-fat study we were aware of the possibility 
that triglycerides could increase, because of the known effect in that direction by the 
concomitant increase of the carbohydrate intake [82]. In that context it was a positive 
result that the triglyceride concentrations were unaffected. One explanation for this 
finding is that the triglyceride increasing effect of carbohydrates is weakened by the 
simultaneously increased fibre intake [82]. A moderate increase in the intake of marine 
n-3 fatty acids may also have contributed. A third explanation could be the slightly 
negative energy balance, which (unintentionally) was a result of the low-fat diet.  
One may anticipate that a reduction of saturated fat and a concomitant increase in fibre 
intake would lower total cholesterol [149,150]. It is however noteworthy that such an 
effect was observed after only 3 d of diet alteration. On the other hand, a reduction of 
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HDL cholesterol was not unexpected in view of the markedly reduced intake of fat 
[149-151].  
Lipoprotein subclasses. My first incentive to measure lipoprotein subclass variables 
was the results of Dunstan DW et al, namely that 3.6 g/d n-3 fatty acids (from fatty fish, 
not supplement) added a low fat diet for 8 wk increased the levels of large HDL (HDL2) 
but decreased the levels of small HDL (HDL3), explaining the observation that the total 
HDL cholesterol did not change [152]. Our results of decreased particle concentration 
of small HDL (Paper III) are in accordance with the results of Dunstan WE [152]. 
Taken together with the reduced VLDL size and reduced particle concentration of large 
VLDL these results can be viewed as anti-atherogenic since they reflect a rapid removal 
of plasma triglycerides. As to the tendency for increased particle concentration of small 
LDL this could be a consequence of a n-3 fatty acid induced moderate reduction of 
insulin sensitivity in the liver [153]  
5.2.4 Adipocyte hormone results. 
In observational studies low levels of adiponectin is usually associated with insulin 
resistance; however this was not found in the n-3 supplement study (Paper II). The 
absence of effect could be due to a neutralizing effect by fatty acid oxidation, which was 
increased at the end of the intervention study. Indeed, previous reports indicate that 
increased fatty acid oxidation per se increases adiponectin levels [50]. 
The lack of effect on leptin concentrations by n-3 fatty acid supplementation (Paper II) 
could, at least in part, be due to the stability of energy intake, fat intake, and body fat 
mass throughout the study (since leptin levels are regulated, at least in part, by changes 
in these [51,154]).  
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 6. Conclusions 
 
To conclude: 
1. A 3-day low-fat diet reduced fasting but not day-time blood glucose 
concentrations in subjects with type 2 diabetes and hypertriglyceridemia. Insulin 
sensitivity and insulin secretion were not affected, nor concentrations of 
triglycerides and free fatty acids. Total and HDL cholesterol concentrations were 
reduced, as were leptin concentrations. Adiponectin concentrations were 
increased (Paper I). 
2. A 9 wk intervention with a high dose of marine n-3 fatty acids (fish oil) 
increased fasting and day-time blood glucose concentrations in subjects with 
type 2 diabetes and normal levels of triglycerides. These effects were due to 
increased insulin resistance as documented by isoglycemic hyperinsulinemic 
clamps. The intervention with fish oil time-dependently increased fat oxidation, 
i.e.  after 9 but not after 1 wk of treatment (Paper II).  
3. The fish oil intervention did not affect plasma lipids (triglycerides, total 
cholesterol) or lipoprotein lipids (LDL cholesterol, HDL cholesterol, oxidized 
LDL). However, lipoprotein subclass qualities were affected: i.e. the VLDL size, 
large VLDL and small HDL particle concentrations were all reduced (Paper III). 
The effects on these lipoprotein subclasses occurred concomitant with a decrease 
in insulin sensitivity.  
4. In subjects with type 2 diabetes and normal levels of triglycerides adding an n-3 
fatty acid emulsion to a standard lipid emulsion did not affect insulin sensitivity, 
energy metabolism or markers of oxidative stress as measured during a 4 h 
hyperinsulinemic clamp (Paper IV). 
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